Beat The Denominator

The recent price drop in Hims & Hers Health (HIMS), due to a Department of Justice referral, presents a high-risk, high-reward opportunity for long-term investors. The core thesis is that HIMS is intentionally challenging pharmaceutical patents on GLP-1 drugs to solidify its disruptive, low-cost business model. Despite negative investor sentiment, the company has a strong customer base that values its significantly cheaper products. For investors with a multi-year timeframe, accumulating shares at current suppressed levels could be a strategic entry point. However, be aware that the legal battle could suppress the stock price for months or even years, making it unsuitable for short-term traders.

The recent sell-off in Hims & Hers Health (HIMS) is viewed as a buying opportunity, as legal and competitive threats are considered overstated. For long-term exposure to the weight-loss market, Eli Lilly (LLY) is positioned to dominate with its next-generation drug retatrutide, expected around late 2026. Investors should be cautious on Novo Nordisk (NVO) due to significant long-term risks from both compounded alternatives and superior competition from LLY. The entire GLP-1 drug theme is a short-term opportunity that will likely be disrupted within the next 2-3 years. Lastly, coupon providers like GoodRx (GDRX) are considered unattractive investments with weak business models and should be avoided.

For long-term investors, consider holding Bitcoin (BTC) for at least five years, but be prepared for significant price volatility. To potentially amplify Bitcoin returns, high-risk investors can look at MicroStrategy (MSTR), which is structured to outperform BTC over time with a long-term view towards $1,000 per share. A more balanced option is the preferred stock "Strike", which offers a 10%+ yield and upside participation only after MSTR's stock price exceeds $1,000. This instrument is designed to reduce downside risk while providing income as the long-term thesis plays out. Finally, investors should avoid leveraged futures products like MSTX and B2, as they are not designed for long-term holding and carry a high risk of total loss.

The current "extreme fear" in the Bitcoin market presents a potential buying opportunity for long-term investors. For leveraged exposure to BTC, consider MicroStrategy (MSTR), which offers a structurally sound way to amplify Bitcoin's price movements. Despite this leverage, MSTR is financially stable and can reportedly withstand a Bitcoin price drop to $8,000. The recommended strategy for both assets is to buy and hold for the long term, ignoring short-term market volatility. Investors should also monitor MSTR's development of its "Stretch" initiative for future growth.

Consider the current market sell-off a buying opportunity for long-term positions in Bitcoin (BTC) and Solana (SOL), which are viewed as foundational assets for the future of finance. Invest in high-conviction disruptive technology companies like Tesla (TSLA) and Palantir (PLTR), as their recent price drops are seen as irrational and disconnected from their strong fundamentals. Avoid investing in "Old World" stocks such as Philip Morris (PM) and UPS (UPS), as their business models face long-term decline. Watch for a potential Bitcoin (BTC) recovery towards $62,000, which could trigger a short squeeze and accelerate price gains. Crucially, do not use leverage in these volatile assets, as forced liquidations are the primary risk to investors in the current market.

Consider Hims & Hers Health (HIMS) as a key investment opportunity, as its stock price appears disconnected from its recent launch of a low-cost, oral GLP-1 weight loss drug. The company is offering its compounded oral semaglutide at just $49 per month, directly challenging expensive brand-name competitors. This disruptive pricing poses a significant threat to legacy pharmaceutical companies like Novo Nordisk (NVO), which is viewed as a stock to avoid due to competitive and legal pressures. For long-term exposure to the GLP-1 theme, Eli Lilly (LLY) is positioned as a strong innovator with its next-generation drug, Retatrutide, expected around the end of 2026. The core strategy involves investing in the disruption of the high-priced drug market through companies like HIMS and long-term innovators like LLY.

Consider a long-term position in MicroStrategy (MSTR), as its leveraged Bitcoin strategy could drive the stock towards a $1,000 price target despite expected short-term volatility. Investors should hold Bitcoin (BTC) for the long term, as institutional buying is expected to provide price support. For a lower-risk alternative focused on yield, consider MicroStrategy's preferred shares, with STKH being a favored option. As a "pick-and-shovel" play on the growth of smart contracts, Coinbase (COIN) offers exposure to the Ethereum ecosystem through its Base network. For direct investment in smart contract platforms, Solana (SOL) is presented as a strong contender that could outperform Ethereum.

SoFi (SOFI) is highlighted as a strong buy opportunity, with analysts suggesting its fair value is between $28-$30 based on outstanding performance. Consider the long-term potential of Hims & Hers (HIMS), which just launched a groundbreaking Grail cancer test but saw its stock fall, creating a potential entry point. Similarly, Bitcoin miners like CleanSpark (CLSK) have become more profitable due to a mining difficulty drop, yet their stocks are being sold off. This market is ignoring strong fundamentals in growth stocks, punishing even companies with great earnings like AMD. Given this indiscriminate selling, investors should prioritize capital preservation, as this bear market could persist for another year.

For long-term investors, the primary strategy is to accumulate and hold Bitcoin (BTC), using volatility as a buying opportunity without using leverage. For those seeking amplified, long-term exposure to Bitcoin, consider MicroStrategy (MSTR) as a high-conviction alternative. MSTR's corporate debt structure is designed to avoid forced selling during downturns, unlike personal leveraged trading. It is critical to avoid high-leverage perpetual futures, as they carry an extreme risk of liquidation and capital loss. The entire thesis for both BTC and MSTR depends on Bitcoin avoiding a long-term price collapse to the $20,000 level.

The recent downturn in high-growth technology stocks like NVIDIA (NVDA) and Broadcom (AVGO) is viewed as a significant buying opportunity for long-term investors. Avoid rotating into perceived "safe" assets like consumer staples (PEP, MDLZ) and US government bonds, which are considered poor investments due to low growth and hidden risks. Reconsider holding gold as a long-term safe haven because of potential supply increases from new discoveries and space mining. Instead, consider Bitcoin (BTC) as a superior store of value due to its digitally enforced, fixed supply. For broad market exposure, favor the innovative, rules-based NASDAQ index over the S&P 500.

Consider buying SoFi (SOFI), as its strong performance suggests the stock is significantly undervalued with a potential price target in the $28 to $30 range. The recent sell-off in new-age brokerages presents an opportunity, with Robinhood (HOOD) highlighted as a buy due to its low valuation and market share gains. Circle (CRCL) is presented as a high-conviction investment, as its massive growth in the USDC stablecoin market is disconnected from its beaten-down stock price. The current dip in Solana (SOL) is viewed as an irrational sell-off and a buying opportunity for a project that is reportedly "firing on all cylinders." For Bitcoin (BTC), investors should adopt a long-term perspective, using current price weakness to study the asset and plan to hold for at least four to five years.

The current market sell-off is creating significant buying opportunities in high-quality, disruptive growth stocks. Consider the recent drop in Robinhood (HOOD), which is described as a "buyable" best-in-class broker that is deeply oversold. SoFi (SOFI) is another strong fintech play to buy on the dip, as it is "firing on all cylinders" after a billion-dollar quarter despite recent stock weakness. Look into Hims & Hers (HIMS) before its upcoming Super Bowl ad, as the stock is considered "ridiculously cheap" with major catalysts on the horizon. The core thesis is that the market is ignoring strong fundamentals, presenting a clear dislocation between price and value for these companies.

A high-conviction opportunity is STRC, a MicroStrategy-issued asset expected to return to a price of 100, supported by a mechanism that increases its yield to attract buyers. For broader exposure, MicroStrategy (MSTR) is demonstrating remarkable resilience and is considered a more stable, leveraged play on Bitcoin. With the Fear and Greed Index indicating 'Extreme Fear', now may be a strategic time for long-term investors to accumulate Bitcoin (BTC). The success of STRC is expected to directly fund more Bitcoin purchases, creating a positive feedback loop for the entire strategy. Investors should focus on these long-term signals rather than short-term technical analysis, which is viewed as unreliable.

For investors seeking high-growth opportunities at a low valuation, consider Chinese electric vehicle maker XPeng (XPEV). The company is executing a Tesla-like strategy in EVs, autonomous driving, and robotics, but trades at a fraction of the valuation while nearing profitability. Another deeply undervalued opportunity is Luckin Coffee (LKNCY), which is rapidly gaining market share from Starbucks in China. Luckin's highly addictive, gamified mobile app drives strong customer loyalty and impressive growth, yet the stock trades at an extremely low multiple. Both companies present a compelling high-risk, high-reward thesis for those willing to invest in the out-of-favor Chinese market.

For income-focused investors, consider the debt instrument Stretch (STRC), which offers a high 11.25% tax-deferred yield with significantly lower volatility than holding crypto directly. This investment is a bet that Bitcoin (BTC) will not crash below its collateral-backing price of $15,400. For long-term growth, view the current market fear as a buying opportunity to accumulate Bitcoin (BTC) for a multi-year hold. The speaker maintains a high-conviction personal price target of $770,000 for BTC by the early 2030s. Alternatively, investing in MicroStrategy (MSTR) stock provides a leveraged way to gain exposure to Bitcoin's long-term potential.

The current weakness in Bitcoin (BTC) is viewed as a long-term buying opportunity for investors targeting a potential price of $800,000 by the 2030s. For high-conviction bulls, MicroStrategy (MSTR) offers a leveraged play on Bitcoin, aiming to amplify returns by approximately 1.5x for those willing to hold until at least 2031. More conservative investors can consider MicroStrategy's "Stretch" instrument, which is designed to capture the first 11% of Bitcoin's annual return with significantly lower volatility. For direct and simple exposure, the iShares Bitcoin Trust (IBIT) provides a way to invest in Bitcoin through a standard brokerage account. Focus on a long-term horizon, as short-term price movements are highly unpredictable.

The current "growth crash" is viewed as an irrational sell-off, creating potential long-term buying opportunities in fundamentally strong companies. Consider SoFi (SOFI), which is seen as "dirt cheap" given its strong user growth and profitability are not reflected in its stock price. Similarly, Hims & Hers (HIMS) is presented as an undervalued opportunity due to its high-growth, 90%+ recurring subscription revenue. For those seeking an inflation hedge, Bitcoin (BTC) has recently outperformed traditional markets and assets like Gold. For leveraged exposure to this theme, MicroStrategy (MSTR) offers a higher-risk, higher-reward way to invest in Bitcoin, with its stock historically moving 1.5x the price of the underlying asset.

Consider a long-term investment in Hims & Hers Health (HIMS), as the market may be undervaluing its strategic shift from sexual health into a comprehensive longevity and preventative care platform. The company is leveraging its AI-powered MedMatch technology to offer personalized, low-cost health solutions, positioning it as a key way to invest in the growing longevity theme. This disruptive focus on prevention poses a direct threat to the business models of traditional "sick care" companies. As a result, investors could consider a bearish stance on dialysis providers like DaVita (DVA) and Fresenius Medical Care (FMS). The core thesis is that as HIMS helps prevent chronic diseases, demand for treatment-focused services offered by companies like DVA and FMS may decline over the long term.

Consider the current market sell-off in innovative "future" stocks like Tesla (TSLA) and Microsoft (MSFT) as a potential buying opportunity for long-term investors. Be cautious of chasing the recent strength in "old world" stocks like AT&T (T), which may face significant long-term disruption risk. For a high-conviction, leveraged bet on Bitcoin, view MicroStrategy (MSTR) as a core holding for a 2030 and beyond timeframe. Expect MSTR to be more volatile than Bitcoin, but it offers amplified exposure for those who believe in the long-term debasement of fiat currency. Use periods of price weakness to study and accumulate Bitcoin (BTC) itself, treating it as a foundational asset for the next decade rather than a short-term trade.

Consider Tesla (TSLA) as a long-term, high-risk, high-reward investment, with its value based on future projects in AI, robotics, and energy. The core investment thesis relies on the successful rollout of its Robotaxi service and the Optimus robot, which is planned for production by the end of 2026. Be prepared for significant short-term price volatility due to high spending, which may create buying opportunities for long-term believers. For investors attracted to this type of visionary company, Palantir (PLTR) is highlighted as a similar unique investment with no direct peers. This bullish outlook on US tech is strengthened by the belief that geopolitical tensions will protect companies like Tesla from Chinese competition in Western markets.